- All > Medicine Information and Evidence for Policy > Medicines Policy
- All > Medicine Information and Evidence for Policy > Monitoring and Evaluation
(1998; 48 pages) [French]
For a number of years, countries and DAP have been active in better monitoring and evaluating their own work. However, an analysis of these activities shows that (1) governments and other important players do not have all the tools needed to evaluate the effects of reforms in the pharmaceutical sector and to interpret changes; (2) the Action Programme on Essential Drugs could be much more systematic in its approach to assessing whether its work is sufficiently relevant to countries' needs and whether its support contributes to measurable changes in the national situation.
The paper will therefore review these two aspects. It will specifically look at
- monitoring and evaluating national drug policies and
- measuring the effects of DAP's work.